Viking Thera (VKTX) Stock Price, Quote & News

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selectiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4660

Website: www.vikingtherapeutics.com

Address:

9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

_Nelisso Jan. 25 at 10:05 PM

If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $LEGN $VKTX $ROLR $BTBT /

0 · Reply

TheDiscerner Jan. 25 at 9:41 PM

Winner winner $NVO $LLY $VKTX

1 · Reply

biolover Jan. 25 at 9:39 PM

$VKTX biggest issue with Attain maintain trial ( u can look it up ) is $LLY reporting GI issue C/w previous trials. If people face 24% vomit rate despite slow orfor titration then don’t beleive it will be that successful and with 5 kg wt gain For $NVO sema there are ongoing trials. But u probably have to titrate 1-4-9-25 mg over 4 months. So u may gain some wt unless u work on it. Vomit rate with oral sema de novo 30%. Uncertain how much after tirzapetide. But again Orfo seems to cause GI issues post TZP although Lilly provided no details

0 · Reply

Cookiemd Jan. 25 at 8:46 PM

$VKTX Question for someone more knowledgeable…If I’m on a GLP1/GIP and side effects wain over time and then I switch to an oral GLP1/GIP do I still need to worry about those side effects that have wained over time or would the reemerge when I switch over? I would think if it’s the same drug they would not…..

1 · Reply

saifnila2 Jan. 25 at 8:36 PM

$VKTX market signaling sell off on impending government shutdown.lets see what the futures show . Government fighting between Republicans and democrats starts with new furor again.

0 · Reply

biolover Jan. 25 at 7:59 PM

$RVMD $VKTX $MRK ends talk with RVMD Are they going to drop it like they did to Viking a year ago ? I doubt it as it is a bio bull market now . May drop a little but not for long. I thought $30 B was too much risk given many other RAS inh in development although RVMD may reach > $30 on its own ina couple of years. MRK is back into obesity. Its management is very weird and hard to understand .

1 · Reply

Stockman824 Jan. 25 at 5:35 PM

$VKTX BIC coupled with all the serious talk at JPM of BPers showing significant interest in Viking = HUGE PARTNERSHIP

1 · Reply

DG20 Jan. 25 at 5:28 PM

$VKTX Amylin increases side effects of GLPs. GIP is the only gut hormone that decreases side effects of GLPs. Even with “pill fatigue” oral VK2735 was far more tolerable than PO Amycretin and SQ MET-097i…

0 · Reply

nlrmandate Jan. 25 at 5:25 PM

$VKTX love love love this entire report; particularly love how much they focused on Vikings unique ability for maintenance (including detailed info on why Vikings is well positioned for maintenance); also love the M&A comments last paragraph.....awesome report....thanks to @biolover

2 · Reply

biolover Jan. 25 at 5:20 PM

$VKTX from recent WB

1 · Reply

Viking Therapeutics, Inc. (VKTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:19 PM EST - 12 days ago

Appetite for weight-loss deals broader than visible, Viking CEO says

Jan 12, 2026, 7:00 AM EST - 13 days ago

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Jan 8, 2026, 7:00 AM EST - 17 days ago

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Jan 7, 2026, 7:00 AM EST - 18 days ago

Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer

Jan 5, 2026, 4:03 PM EST - 20 days ago

Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 10:57 AM EST - 20 days ago

Novo Nordisk's weight-loss pill is available. Here's why Lilly's and Viking's stocks are down.

LLY NVO

Jan 3, 2026, 10:00 AM EST - 22 days ago

Viking Therapeutics: The Obesity Drugs Gold Rush Is Far From Over

Jan 1, 2026, 2:13 AM EST - 24 days ago

Viking Therapeutics: A Wide-Open Oral GLP-1 Market

Dec 28, 2025, 9:40 AM EST - 4 weeks ago

Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain

Dec 6, 2025, 8:57 AM EST - 7 weeks ago

Viking Therapeutics: Prepping For A Critical 2026

Nov 25, 2025, 4:05 PM EST - 2 months ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 1:58 PM EST - 2 months ago

3 Weight-Loss Drug Stocks To Consider For 2026

LLY NVO

Nov 19, 2025, 4:48 AM EST - 2 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 2:55 AM EST - 2 months ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 6, 2025, 7:05 AM EST - 2 months ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Nov 5, 2025, 10:01 AM EST - 2 months ago

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Nov 4, 2025, 4:05 PM EST - 2 months ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

Oct 29, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 23, 2025, 10:42 AM EDT - 3 months ago

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Oct 23, 2025, 10:05 AM EDT - 3 months ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 22, 2025, 7:33 PM EDT - 3 months ago

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 7:05 AM EDT - 3 months ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 15, 2025, 4:05 PM EDT - 3 months ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 4, 2025, 9:44 AM EDT - 4 months ago

Viking Therapeutics: A Speculative Buy

Sep 28, 2025, 2:00 PM EDT - 4 months ago

Viking Therapeutics: Overdue For Gains

Sep 23, 2025, 1:53 PM EDT - 4 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 22, 2025, 1:55 PM EDT - 4 months ago

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Sep 8, 2025, 5:43 PM EDT - 4 months ago

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 23, 2025, 6:57 AM EDT - 5 months ago

Viking: Still On Track, But The Compass Needs Recalibration

Aug 20, 2025, 8:52 PM EDT - 5 months ago

Viking Therapeutics: Panic Creates Opportunity

Aug 20, 2025, 9:50 AM EDT - 5 months ago

Viking Therapeutics: What's Happening With VKTX Stock?

Aug 19, 2025, 9:38 PM EDT - 5 months ago

Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone'

Aug 19, 2025, 6:27 PM EDT - 5 months ago

Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data

Aug 19, 2025, 2:44 PM EDT - 5 months ago

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Aug 19, 2025, 1:45 PM EDT - 5 months ago

The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin

Aug 19, 2025, 12:19 PM EDT - 5 months ago

Viking Therapeutics plummets on new obesity drug data. Here's a breakdown

Aug 19, 2025, 12:05 PM EDT - 5 months ago

Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results

Aug 19, 2025, 12:03 PM EDT - 5 months ago

Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success

Aug 19, 2025, 11:00 AM EDT - 5 months ago

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

Aug 19, 2025, 9:39 AM EDT - 5 months ago

Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data

Aug 19, 2025, 9:28 AM EDT - 5 months ago

Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks

LLY

Aug 19, 2025, 9:11 AM EDT - 5 months ago

Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.

Aug 19, 2025, 8:57 AM EDT - 5 months ago

Viking Therapeutics stock tumbles 37% today, but here's why you should ‘HOLD'

Aug 19, 2025, 7:18 AM EDT - 5 months ago

Viking Therapeutics' oral weight-loss pill meets expectations in mid-stage study

Aug 19, 2025, 7:08 AM EDT - 5 months ago

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Aug 18, 2025, 8:56 PM EDT - 5 months ago

Viking Therapeutics: Still On Track

Jul 25, 2025, 10:15 AM EDT - 6 months ago

Viking Therapeutics Q2: Confidently Continuing The Recovery

Jul 23, 2025, 9:45 PM EDT - 6 months ago

Viking Therapeutics, Inc. (VKTX) Q2 2025 Earnings Call Transcript

_Nelisso Jan. 25 at 10:05 PM

0 · Reply

TheDiscerner Jan. 25 at 9:41 PM

Winner winner $NVO $LLY $VKTX

1 · Reply

biolover Jan. 25 at 9:39 PM

0 · Reply

Cookiemd Jan. 25 at 8:46 PM

1 · Reply

saifnila2 Jan. 25 at 8:36 PM

$VKTX market signaling sell off on impending government shutdown.lets see what the futures show . Government fighting between Republicans and democrats starts with new furor again.

0 · Reply

biolover Jan. 25 at 7:59 PM

1 · Reply

Stockman824 Jan. 25 at 5:35 PM

$VKTX BIC coupled with all the serious talk at JPM of BPers showing significant interest in Viking = HUGE PARTNERSHIP

1 · Reply

DG20 Jan. 25 at 5:28 PM

0 · Reply

nlrmandate Jan. 25 at 5:25 PM

2 · Reply

biolover Jan. 25 at 5:20 PM

$VKTX from recent WB

1 · Reply

biolover Jan. 25 at 4:54 PM

$VKTX been taking about emerging tolerability of vanquish 1 Compare to amycretin. This is from lancet paper Look at DC rate among higher doses and even the vomit rate was calculated for all ITT pts ( like 4/16 pts in the 5 mg dose. But they claim a lot of DC not due to side effects ? So the vomit rate is significantly higher than 25% even in the smaller 5 mg. If you look at 20 or 60 mg .. the vomit rate is enormous ( although placebo also had high vomit from sc. weird. Very small placebo sample ..). Look at slow escalation rate . Novo can’t escalate anymore. It is a poor drug. Doesn’t matter how many phase 3 trials they would start this year.

1 · Reply

I_like_em_stock Jan. 25 at 4:00 PM

$VKTX I'm full of hopium on this one. Feels like something is gonna happen.

0 · Reply

nlrmandate Jan. 25 at 11:40 AM

$VKTX very very

0 · Reply

NoFearHere Jan. 25 at 1:58 AM

$VKTX I'm aging awaiting 100.00 again 🤨

1 · Reply

NYG4ever Jan. 25 at 1:36 AM

$VKTX questions for @biolover and the test of my esteemed Bio pros - if we launched a maintenance dosing study with Subq and PO wouldnt that also be enough evidence that PO will go to Ph3? i guess im not understanding how this wouldnt go to phase 3 given the existing programs underway.

1 · Reply

Theflash88 Jan. 24 at 11:39 PM

$VKTX Only thing we can do is call or write investor relations. I will.

0 · Reply

Theflash88 Jan. 24 at 11:37 PM

$VKTX All the negative posts! Don’t blame you.. I’ve been in this stock for over 2 years and actually, stupidly bought some at the $85 offering.. figuring it was a $150+ stock.. Been downhill since.. other GLP companies with a weaker, early stage drug got bought out already or at least their stock price has skyrocketed.. GPCR.. MTSR.. etc I’m still confident we will be rewarded but it has been a very weary journey with little hope from management. GL all My 2nd largest holding.

0 · Reply

biolover Jan. 24 at 10:07 PM

$VKTX $LLY started Triumph 9 with 104 wks if retatrutide in obese non diabetics Lilly likely doing slow escalation and longer duration with Trumph 9 -600 pt. Probably unhappy with DC rate in Trimuph 4 and likely other ongoing retatrutide trials. Lilly will start soon to feel heat coming from VK2735 ( I know there are people here who only think big vs small.. and not from drug qualities ) But VK2735 in the hands of $ABBV , $BMY even MRK could pose a serious challenge to Lilly dominance. Unlike $NVO crowd here who are excited about oral semaglutide ( that pts have not tried in market for long yet ) , there is nothing still in NVo pipeline that poses serious threat to Lilly.

1 · Reply

Markus_Montag Jan. 24 at 7:56 PM

$VKTX Buying more in early Feb

0 · Reply

whiskyqueen Jan. 24 at 7:15 PM

$VKTX Hopefully we clear a buyout before the Civil War…Come on Brian, I need a little more cushion here 😂

3 · Reply

vu_jade Jan. 24 at 5:48 PM

$VKTX it’s on automatic pilot to the moon…

1 · Reply

ians Jan. 24 at 5:39 PM

$VKTX Ignore the fear-mongers & bashers. Seize the opportunity instead. BUY & Accumulate😉 Down -3.9% EOD, -8.4% YTD with pending Q4'25 earnings CC on Feb 04. With EOP2 FDA meeting minutes on deck that has to potential to confirm oral VK2735 is going straight from P2A-->P3. Hmmm... Sounds like a buying opportunity to me 🤑☘️💎

0 · Reply

Market Cap	3.64B
Revenue (ttm)	0.00
Net Income (ttm)	-109.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,835,600
Avg Vol	3,110,802
Day's Range	N/A - N/A
Shares Out	113.04M
Stochastic %K	42%
Beta	0.71
Analysts	Strong Sell
Price Target	$93.06